Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9732126 | 0.98 | LMNA (0.62) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL859440 | 0.86 | MAPT (0.57) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL830265 | 0.84 | SMN1; SMN2 (0.48) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL29420513 | 0.84 | SMN1; SMN2 (0.48) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL8103092 | 0.82 | POLB (0.66) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL3647767 | 0.82 | MAPT (0.61) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL23412192 | 0.81 | NCF1 (0.56) | LMNAPOLBKDM4EHSD17B10NQO2 | |
| SCHEMBL25912335 | 0.81 | DHODH (0.48) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL4748376 | 0.80 | LMNA (0.55) | LMNAPOLBKDM4EHSD17B10HPGD | |
| SCHEMBL1043638 | 0.79 | KDM4E (0.65) | LMNAPOLBKDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220064118-A1 | Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-20220064118-A1 | Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| EP-3649110-B1 | MYCOBACTERIUM-TUBERCOLOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS ANTITUBERCULOSIS DRUG | UNIV DORTMUND TECH (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2021-08-03 | — | — | US | disclosed |
| EP-3848355-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | The Trustees Of The University Of Pennsylvania (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848355-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | The Trustees Of The University Of Pennsylvania (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11001558-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-05-11 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004091485-A2 | AMINOQUINOLINE COMPOUNDS | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209902-A1 | e.g., 1,4-bis[2,6-dimethylquinolin-4ylamino]butane; used to treat inflammatory and immune diseases by binding to CXCR3 receptors. | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | US | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| US-5506235-A | Quinoline derivatives as immunostimulants | PFIZER INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0387821-B1 | 2-Alkyl-4-arylmethylaminoquinolines, their use and medicines containing them | BASF AG (DE) | 1994-08-24 | — | — | EP | disclosed |
| EP-0597003-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993003030-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0387821-A2 | 2-Alkyl-4-arylmethylaminoquinolines, their use and medicines containing them | BASF Aktiengesellschaft (DE) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | LMNA 4584/4885POLB 3759/4885KDM4E 4780/4885 |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | LMNA 1633/4885POLB 2264/4885KDM4E 1279/4885 |
| US-20040209902-A1 | e.g., 1,4-bis[2,6-dimethylquinolin-4ylamino]butane; used to treat inflammatory and immune diseases by binding to CXCR3 receptors. | CXCR3, CXCL10, CXCR1 | LMNA 4297/4885POLB 3281/4885KDM4E 1504/4885 |
| US-11001558-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | LMNA 1633/4885POLB 2264/4885KDM4E 1279/4885 |
| US-20220064118-A1 | Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy | SQSTM1, ATG7, BECN1 | LMNA 1633/4885POLB 2264/4885KDM4E 1279/4885 |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TXNRD3, TXNRD1, TXN | LMNA 3934/4885POLB 1960/4885KDM4E 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.